Atrys Health, S.A. (ATRY.MC)

EUR 2.85

(0.35%)

Long Term Debt Summary of Atrys Health, S.A.

Atrys Health, S.A.'s latest annual long term debt in 2023 was 162.72 Million EUR , down -22.69% from previous year.
Atrys Health, S.A.'s latest quarterly long term debt in 2024 Q1 was 153.57 Million EUR , down -5.62% from previous quarter.
Atrys Health, S.A. reported annual long term debt of 210.48 Million EUR in 2022, up 17.63% from previous year.
Atrys Health, S.A. reported annual long term debt of 178.92 Million EUR in 2021, up 200.05% from previous year.
Atrys Health, S.A. reported quarterly long term debt of 153.57 Million EUR for 2024 Q1, down -5.62% from previous quarter.
Atrys Health, S.A. reported quarterly long term debt of 189.62 Million EUR for 2023 Q3, down -11.37% from previous quarter.

Annual Long Term Debt Chart of Atrys Health, S.A. (2023 - 2012)

Historical Annual Long Term Debt of Atrys Health, S.A. (2023 - 2012)

Year	Long Term Debt	Long Term Debt Growth
2023	162.72 Million EUR	-22.69%
2022	210.48 Million EUR	17.63%
2021	178.92 Million EUR	200.05%
2020	59.63 Million EUR	96.71%
2019	30.31 Million EUR	99.86%
2018	15.16 Million EUR	51.14%
2017	10.03 Million EUR	-3.66%
2016	10.41 Million EUR	-9.93%
2015	11.56 Million EUR	3.64%
2014	11.15 Million EUR	6.08%
2013	10.51 Million EUR	0.76%
2012	10.44 Million EUR	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q2	172.06 Million EUR	12.04%
2024 Q1	153.57 Million EUR	-5.62%
2023 Q3	189.62 Million EUR	-11.37%
2023 FY	162.72 Million EUR	-22.69%
2023 Q1	213.94 Million EUR	1.65%
2023 Q4	162.72 Million EUR	-14.18%
2023 Q2	213.94 Million EUR	0.0%
2022 Q1	210.39 Million EUR	17.59%
2022 FY	210.48 Million EUR	17.63%
2022 Q4	210.48 Million EUR	0.03%
2022 Q3	210.41 Million EUR	0.01%
2022 Q2	210.39 Million EUR	0.0%
2021 Q4	178.92 Million EUR	0.03%
2021 Q1	162.04 Million EUR	171.74%
2021 FY	178.92 Million EUR	200.05%
2021 Q2	162.04 Million EUR	0.0%
2021 Q3	178.86 Million EUR	10.38%
2020 Q2	32.03 Million EUR	0.4%
2020 Q4	59.63 Million EUR	0.1%
2020 Q1	31.9 Million EUR	5.25%
2020 FY	59.63 Million EUR	96.71%
2020 Q3	59.57 Million EUR	85.96%
2019 FY	30.31 Million EUR	99.86%
2019 Q2	14.52 Million EUR	1.07%
2019 Q4	30.31 Million EUR	0.42%
2019 Q3	30.18 Million EUR	107.88%
2019 Q1	14.36 Million EUR	-5.27%
2018 Q4	15.16 Million EUR	1.09%
2018 FY	15.16 Million EUR	51.14%
2018 Q2	799.29 Thousand EUR	-91.7%
2018 Q1	9.63 Million EUR	-4.04%
2018 Q3	15 Million EUR	1777.14%
2017 FY	10.03 Million EUR	-3.66%
2017 Q4	10.03 Million EUR	2.04%
2017 Q3	9.83 Million EUR	-7.49%
2017 Q2	10.63 Million EUR	1.2%
2017 Q1	10.5 Million EUR	0.85%
2016 Q2	1.26 Million EUR	0.0%
2016 Q1	1.26 Million EUR	0.0%
2016 FY	10.41 Million EUR	-9.93%
2016 Q4	10.41 Million EUR	1.23%
2016 Q3	10.29 Million EUR	716.28%
2015 FY	11.56 Million EUR	3.64%
2014 FY	11.15 Million EUR	6.08%
2013 FY	10.51 Million EUR	0.76%
2012 FY	10.44 Million EUR	0.0%

Peer Long Term Debt Comparison of Atrys Health, S.A.

Name	Long Term Debt	Long Term Debt Difference
Biotechnologies Assets SA	5.15 Million EUR	-3057.159%
Oryzon Genomics S.A.	3.45 Million EUR	-4615.855%
Pharma Mar, S.A.	27.03 Million EUR	-501.886%
Laboratorios Farmaceuticos Rovi, S.A.	52.24 Million EUR	-211.485%